Authors
Berra Koskulu, Tabish Ali, Ilkin Tetik-Altintop, Cleva Villanueva, Maja Gomola, Bradley K McConnell
Published in
Journal of the American Heart Association. Pages e050981. Aug 20, 2026. Epub Aug 20, 2026.
Abstract
Cardiovascular disease remains the leading cause of global mortality, in part because the heart has limited regenerative capacity. Human-induced pluripotent stem cells (hiPSCs) offer a scalable, patient-specific platform for modeling heart disease, advancing drug discovery, and developing regenerative therapies. This review evaluates recent developments in hiPSC technology, beginning with the generation of patient-specific models of inherited arrhythmias and cardiomyopathies. We examine progress in directing hiPSCs into specialized lineages, including cardiomyocytes, pacemaker cells, and Purkinje fibers, by highlighting key developmental signaling pathways and transcriptional regulators. Furthermore, we discuss emerging strategies for cell and therapeutic delivery, such as bioengineered patches and hydrogels, and address key challenges in cell maturation and functional integration. Finally, we review current clinical trials assessing the safety of hiPSC-based treatments for heart failure and conduction disorders. These advancements underscore the dual potential of hiPSCs as essential research tools and as aspirational therapeutic resources.
PMID:
42622208
Bibliographic data and abstract were imported from PubMed on 20 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 12
- Comments 0